Company News & Events

ORYZON to present at the Neuroscience Innovation Forum in San Francisco

4 January 2018


• The company will also participate at the Trout Annual 1x1 Management Access Event 2018 during the week of the JP Morgan Healthcare Conference

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Dr. Carlos Buesa and Dr. Roger Bullock, Oryzon’s CEO and CMO, will present the recent progresses of ORY-2001 at the Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco on the 7th of January 2018, a day before the JP Morgan meeting. Dr. Buesa will also participate as a panelist in a round table entitled “Advances in Alzheimer’s and other Cognitive Disorders”.


Click here to see the full Press Release


Posted In: 

Share this story